Sudo Biosciences Raises $116M Series B Financing To Advance Potential Best-In-Class Tyk2 Therapeutics Programs Into The Clinic

Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital. The Company has raised a total of $157 million funding since its founding in 2020.